Your browser doesn't support javascript.
loading
Low-dose radiation therapy mobilizes antitumor immunity: New findings and future perspectives.
Zhou, Laiyan; Liu, Yuanxin; Wu, Yuanjun; Yang, Xue; Spring Kong, Feng-Ming; Lu, You; Xue, Jianxin.
Afiliação
  • Zhou L; Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
  • Liu Y; Disaster Medical Center, Sichuan University, Chengdu, China.
  • Wu Y; Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
  • Yang X; Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
  • Spring Kong FM; Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
  • Lu Y; Department of Clinical Oncology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
  • Xue J; Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Int J Cancer ; 154(7): 1143-1157, 2024 Apr 01.
Article em En | MEDLINE | ID: mdl-38059788
ABSTRACT
Radiotherapy has unique immunostimulatory and immunosuppressive effects. Although high-dose radiotherapy has been found to have systemic antitumor effects, clinically significant abscopal effects were uncommon on the basis of irradiating single lesion. Low-dose radiation therapy (LDRT) emerges as a novel approach to enhance the antitumor immune response due to its role as a leverage to reshape the tumor immune microenvironment (TIME). In this article, from bench to bedside, we reviewed the possible immunomodulatory role of LDRT on TIME and systemic tumor immune environment, and outlined preclinical evidence and clinical application. We also discussed the current challenges when LDRT is used as a combination therapy, including the optimal dose, fraction, frequency, and combination of drugs. The advantage of low toxicity makes LDRT potential to be applied in multiple lesions to amplify antitumor immune response in polymetastatic disease, and its intersection with other disciplines might also make it a direction for radiotherapy-combined modalities.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias Limite: Humans Idioma: En Revista: Int J Cancer Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Neoplasias Limite: Humans Idioma: En Revista: Int J Cancer Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China